Gastrointestinal safety and tolerability of non-selective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors

Cleveland Clinic Journal of Medicine

Volumn 69, Issue SUPPL. 1, 2002, Pages

  Peura, David A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

BACTERIAL INFECTION; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER PYLORI; HUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH DISEASE; ARTHRITIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DIGESTIVE SYSTEM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG TOLERANCE; FEMALE; GASTRITIS; MALE; MAXIMUM TOLERATED DOSE; SAFETY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; GASTRITIS; HUMANS; ISOENZYMES; MALE; MAXIMUM TOLERATED DOSE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK ASSESSMENT; SAFETY;

EID: 0036047916     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.suppl_1.si31     Document Type: Review

References (56)

1. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996; 25:279-298.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899.
3. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996; 11:461- 469.
4. Weissmann G. NSAIDS: aspirin and aspirin-like drugs. In: Goldman L, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia: W.B. Saunders, 2000:114-118.
5. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 (suppl 56):18-24.
6. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105:315-383.
7. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin North Am 1996; 6:489-504.
8. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104:390-398.
9. Lipsky LPE, Abramson SB, Crofford L, DuBois RN, Simon LS, van de Putte LBA. The classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25:2298-2303.
10. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987; 147:85-88.
11. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91:213-222.
12. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787-796.
13. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8:18-24.
14. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241-249.
15. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257-263.
16. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-1078.
17. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995; 30:438-444.
18. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety-Study. JAMA 2000; 284:1247-1255.
19. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769-772.
20. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153:1665-1670.
21. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735-740.
22. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310:827-830.
23. Sørensen HT, Mellemkjær L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95:2218-2224.
24. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321:1183-1187.
25. Slattery J, Warlow CP, Shorrock CJ, Langman MJS. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37:509-511.
26. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413-1416.
27. Cryer B, Kimmer MB. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 105:203-303.
28. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine [on] gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989; 34:424-428.
29. Roth SH, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation. Arch Intern Med 1987; 147:1798-1801.
30. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991; 115:195-200.
31. Hudson N, Taha AS, Russell R, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112:1817-1822.
32. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334:1435-1439.
33. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001; 13(suppl):S43-S47.
34. Matheson AJ, Jarvis B. Lansoprarole: an update of its place in the management of acid-related disorders. Drugs 2001; 61:1801-1833.
35. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprarole. Arch Intern Med 2002; 162:169-175.
36. 2-receptor antagonist therapy. Am J Gastroenterol 1997; 92:429-437.
37. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprarole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338:727-734.
38. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719-726.
39. Graham DY. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications-future research needs. Am J Med 2001; 110:585-615.
40. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119:257-262.
41. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998; 41:16-25.
42. Levine JS. Misoprostol and nonsteroidal anti-inflammatory drugs: a tale of effects, outcomes, and costs. Ann Intern Med 1995; 123:309-310.
43. Leandro G, Pilotto A, Franceschi M, Bertin T, Lichino E, DiMario F. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46:1924-1936.
44. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 91:2080-2086.
45. Taha AS, Dahill S, Morran C, et al. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology 1999; 116:254-258.
46. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999; 116:1305-1309.
47. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
48. Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41:459-462.
49. Huang JQ. H. pylori, NSAID use, and risk of peptic ulcer disease: meta-analysis of 5 case control studies. Am J Gastroenterol 2000; 95:A146.
50. Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-973.
51. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160:2993-3003.
52. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117:776-783.
53. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999; 282:1921-1928.
54. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354:2106-2111.
55. Harper S, Bolognese J, Lee M, Watson DJ, Curtis S. Fewer GI-related treatment discontinuations with etoricoxib compared with nonselective cyclooxygenase inhibitors (NSAIDs). In: Abstracts of The American College of Rheumatology 64th Annual Scientific Meeting; October 29-November 2, 2000; Philadelphia, PA. Abstract 1588.
56. Harper S, Lee M, Curtis S, Ng J, Watson DJ, Bolognese J. A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). In: Abstracts of The American College of Rheumatology 64th Annual Scientific Meeting; October 29-November 2, 2000; Philadelphia, PA. Abstract 1590.